News & Updates
Filter by Specialty:
Saroglitazar may lower cardiovascular risk in NAFLD
Treatment with the dual PPAR α/γ agonist saroglitazar helps improve the serum atherogenic lipoprotein profile in patients with nonalcoholic fatty liver disease (NAFLD), regardless of comorbid conditions and statin use, as shown in a study.
Saroglitazar may lower cardiovascular risk in NAFLD
03 Feb 2023
Prediabetes in youngsters linked to a nearly 80 percent increased risk of CVD
Prediabetes in youngsters is associated with an 88 percent lifetime risk of diabetes and a nearly 80 percent higher risk of cardiovascular disease (CVD), researchers from the Chinese University of Hong Kong (CUHK) have reported.
Prediabetes in youngsters linked to a nearly 80 percent increased risk of CVD
30 Jan 2023
Some antihypertensive medications may lower dementia risk
Use of angiotensin II (ATII)-stimulating antihypertensive medication (AHM), angiotensin receptor blockers (ARBs), and dihydropyridine calcium channel blockers (CCBs) helps reduce the risk of dementia over a decade, but this beneficial effect decreases over time, according to a study.
